Watch the video and download the slides
Hemato-oncology
New Molecular Approaches in DLBCL
Dr Brian T. Hill discusses New Molecular Approaches in Diffuse Large B-Cell Lymphoma (DLBCL)
Publication Date
Sep 2021
Dr Hill is the Director of the Lymphoid Malignancies Program and a Staff Physician in the Cleveland Clinic Taussig Cancer Institute. He received his undergraduate degree from Dartmouth College and earned his Ph.D. in genetics through work done at Cold Spring Harbor Laboratory. He received his medical degree from the University of Chicago Pritzker School of Medicine where he also completed his residency in Internal Medicine. He completed his hematology/oncology fellowship at the Cleveland Clinic. His clinical and research focus is in chronic lymphocytic leukemia (CLL) and lymphoma. He is the principal investigator of multiple on-going clinical trials of new cancer treatments including novel cellular therapies
Dr Brian Hill has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Abbvie, AstraZeneca, Genetech, Gilead and Pharmacyclics
Programme summary
Duration 5 MIN
Downloadable resources Yes-
DOWNLOAD THE SLIDES
-
Language(s)
Share this programme
Brought to you by
LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Karyopharm Therapeutics and Menarini Stemline Oncology.
Meet the experts
Other programmes of interest
Video
Oncology Hemato-oncology
Early relapsed/refractory multiple myeloma (RRMM): best practices in management
A 3-part video series on managing early RRMM from leading medical experts
Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael-
Downloadable
Resources -
4 MIN
-
Sep 2024
Oncology Hemato-oncology
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)
Medical experts discuss the latest learnings from clinical practice
Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter-
Downloadable
Resources -
MIN
-
Jun 2024
Conference update
Episode
6
of 6
Oncology Hemato-oncology
Listen to Expert Insights on Late-Breaking Data from ASCO 2023
Episode 6: Lymphoma Update: SWOG S1826 trial
Experts
Dr Mansoor Raza Mirza, Dr Paolo Tarantino, Prof. Alexey V Danilov, Prof. Mark Socinski, Prof. Evan Yu, Prof. Thomas Powles, Assoc. Prof. Gerald Prager-
2 MIN
-
Jun 2023
Oncology Hemato-oncology
Update From ASH 2022
Highlights from the ASH Annual Meeting
Experts
Dr Matthew J. Matasar-
4 MIN
-
Dec 2022
Hemato-oncology
Update from ASCO 2022 – Myeloma
Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)
Experts
Asst. Prof. Hans Lee-
2 MIN
-
May 2022
Podcast
Episode
3
of 3
Hemato-oncology
Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics
Episode 3: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics
Experts
Assoc. Prof. María Victoria Mateos, Dr Alexander M Lesokhin-
Downloadable
Resources -
MIN
-
Mar 2022
